Mirum Pharmaceuticals, Inc. (MIRM) Announces Proposed Common Offering
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/24/2026
- S&P 500, Nasdaq end down on tech stocks, investors weigh Iran moves
- Oil drops more than $2 despite new US sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Wattmore and Eos Energy strike non-exclusive storage software deal
- Grand Canyon Education places CFO on leave amid stock trade probe
- S&P 500, Nasdaq end down on tech stocks, investors weigh Iran moves
- Funds sell $44bn in semiconductors on AI concerns
- RUM Group signs $13.7 billion GPU services deal, issues warrants
Mirum Pharmaceuticals Announces Commencement of Public Offering of Common Stock
December 14, 2020 7:00 AM ESTFOSTER CITY, Calif.--(BUSINESS WIRE)-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases, today announced that it has commenced an underwritten public offering, subject to market and other conditions, to issue and sell $75.0 million of shares of its common stock. In connection with the proposed offering, Mirum expects to grant the underwriters a 30-day option to purchase up to an additional approximately $11.3 million of shares of common stock. There can be no assurance as... More
